Loader

Pathways

PathWhiz ID Pathway Meta Data

PW176662

Pw176662 View Pathway
drug action

Aceprometazine H1 Antihistamine Smooth Muscle Relaxation Action Pathway

Homo sapiens
Aceprometazine is a is a drug with neuroleptic and anti-histamine properties. Although not widely prescribed, it is used in combination with meprobamate for the treatment of sleep disorders in France under the trade name Mepronizine. Aceprometazine, acting as an H1-receptor antagonist can induce sedation by being able to cross the blood-brain-barrier and binding to H1-receptors in the central nervous system. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. H1-antihistamines act on H1 receptors in T-cells to inhibit the immune response, in blood vessels to constrict dilated blood vessels, and in smooth muscles of lungs and intestines to relax those muscles. Allergies causes blood vessel dilation which causes swelling (edema) and fluid leakage.

PW176755

Pw176755 View Pathway
drug action

Aceprometazine H1-Antihistamine Blood Vessel Constriction Action Pathway

Homo sapiens
Aceprometazine is a is a drug with neuroleptic and anti-histamine properties. Although not widely prescribed, it is used in combination with meprobamate for the treatment of sleep disorders in France under the trade name Mepronizine. Aceprometazine, acting as an H1-receptor antagonist can induce sedation by being able to cross the blood-brain-barrier and binding to H1-receptors in the central nervous system.

PW176847

Pw176847 View Pathway
drug action

Aceprometazine H1-Antihistamine Immune Response Action Pathway

Homo sapiens
Aceprometazine is a is a drug with neuroleptic and anti-histamine properties. Although not widely prescribed, it is used in combination with meprobamate for the treatment of sleep disorders in France under the trade name Mepronizine. Aceprometazine, acting as an H1-receptor antagonist can induce sedation by being able to cross the blood-brain-barrier and binding to H1-receptors in the central nervous system. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. H1-antihistamines act on H1 receptors in T-cells to inhibit the immune response, in blood vessels to constrict dilated blood vessels, and in smooth muscles of lungs and intestines to relax those muscles. Allergies causes blood vessel dilation which causes swelling (edema) and fluid leakage.

PW000687

Pw000687 View Pathway
drug action

Acetaminophen Action Pathway

Homo sapiens
Acetaminophen (also named paracetamol or APAP) is not a Nonsteroidal anti-inflammatory drugs (NSAIDs). However, it still can be used to treat pain and fever. Acetaminophen can block prostaglandin synthesis by the action of inhibition of prostaglandin G/H synthase 1 and 2. Prostaglandin G/H synthase 1 and 2 catalyze the arachidonic acid to prostaglandin G2, and also catalyze prostaglandin G2 to prostaglandin H2 in the metabolism pathway. Decreased prostaglandin synthesis in many animal model's cell is caused by presence of acetaminophen.

PW124159

Pw124159 View Pathway
drug action

Acetaminophen Action Pathway (New)

Homo sapiens
Acetaminophen is an oral/IV antipyretic and analgesic drug used to treat fevers and mild to moderate pain. Its exact mechanism is unknown but it is thought to target the cyclooxygenase pathway in the CNS (brain). It does not inhibit the cyclooxygenase pathway in peripheral tissues, an therefore, does not have any peripheral anti-inflammatory effect. The cyclooxygenase (COX) pathway begins in the cytosol with arachidonic acid being formed from membrane phospholipids via phospholipase A2. On the endoplasmic reticulum membrane, arachidonic acid is converted to prostaglandin G2 then to prostaglandin H2 using the enzymes prostaglandin G/H synthase 1 & 2 (COX-1 & COX-2). Prostaglandin H2 leads to the formation of thromboxane A2 (via thromboxane-A synthase), prostacyclin (via prostacyclin synthase) and prostaglandin E2 (via prostaglandin E synthase). Prostaglandin E2 (PGE2) is responsible for mediating pain and fever. Acetaminophen enters the cell through the solute carrier family 22-member 6 transporter and inhibits the COX-1 & COX-2 enzymes on the endoplasmic reticulum membrane. This prevents the production of prostaglandin H2 from arachidonic acid, thereby lowering the concentration of prostaglandin E2 in the cell. Since PGE2 causes pain and fever, reduction of PGE2 would lessen fevers and increase threshold for pain sensation. There are very few side effects associated with acetaminophen, but some people may have allergic reactions which may include itching, rash, difficulty breathing and swelling of face, hands, throat or mouth.

PW144443

Pw144443 View Pathway
drug action

Acetaminophen Drug Metabolism Action Pathway

Homo sapiens

PW000616

Pw000616 View Pathway
drug metabolism

Acetaminophen Metabolism Pathway

Homo sapiens
Acetaminophen (APAP) is metabolized primarily in the liver. Glucuronidation is the main route, accounting for 45-55% of APAP metabolism, and is mediatied by UGT1A1, UGT1A6, UGT1A9, UGT2B15 in the liver and UGT1A10 in the gut. APAP can also by metabolized via sulfation, accounting for 30-35% of the metabolism. In the liver, this step is catalyzed by the sulfotransferases SULT1A1, SULT1A3, SULT1A4, SULT1E1 and SULT2A1. Moreover, APAP can also be activated to form the toxic N-acetyl-p-benzoquinone imine (NAPQI) under the mediation of CYP3A4, CYP2E1, CYP2D6 CYP1A2, CYP2E1 and CYP2A6.

PW132504

Pw132504 View Pathway
metabolic

Acetarsol Drug Metabolism

Homo sapiens
Acetarsol is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Acetarsol passes through the liver and is then excreted from the body mainly through the kidney.

PW146630

Pw146630 View Pathway
drug action

Acetarsol Drug Metabolism Action Pathway

Homo sapiens

PW002090

Pw002090 View Pathway
metabolic

Acetate Metabolism

Escherichia coli
The acetate biosynthesis starts with acetyl-CoA reacting with phosphate through a phosphate acetyltransferase resulting in the release of a coenzyme A and an acetyl phosphate. The latter compound in turn reacts with ADP through an acetate kinase resulting in the release of an ATP and an acetate. The acetate reacts with ATP and coenzyme A through an acetyl-CoA synthase resulting in the release of a diphosphate, an AMP and an acetyl-CoA. Acetyl-CoA can be biosynthesized by acetoacetate reacting with an acetyl-CoA through an acetoacetyl-CoA transferase resulting in the release of an acetate and an acetoacetyl-CoA. The acetoacetyl-CoA reacts with an acetyl-CoA acetyltransferase resulting in the release of an coenzyme A and 2 acetyl-CoA